ARTICLE | Company News
CBT, Bossan partner for combination trials
November 30, 2018 9:39 PM UTC
CBT Pharmaceuticals Inc. (Pleasanton, Calif.) gained exclusive, worldwide rights to develop and commercialize EGFR inhibitor ES-072 outside of Greater China from Zhejiang Bossan Pharmaceutical Co. Ltd. (Hangzhou, China).
CBT and Bossan will jointly develop and conduct clinical trials for ES-072 in combination with CBT's c-Met inhibitor CBT-101 and/or anti-PD-1 mAb CBT-501...